Skip to main content

Table 5 Association between hsCRP and GGT levels, and metabolic syndrome and Insulin resistance, within selected subgroups

From: High-sensitivity c-reactive protein and gamma-glutamyl transferase levels are synergistically associated with metabolic syndrome in community-dwelling persons

  

Metabolic syndrome OR(95% CI).

HOMA-IR ≥2.6† OR(95% CI).

  

Tertile of hsCRP

Tertile of GGT

Tertile of hsCRP

Tertile of GGT

  

1st

2nd

3rd

1st

2nd

3rd

1st

2nd

3rd

1st

2nd

3rd

Characteristics

 

<0.360

0.360-0.800

>0.800 mg/L

<29

29-54

>54 IU/L

<0.280

0.280-0.650

>0.650 mg/L

<18

18-24

>24 IU/L

Age

             

   <65 years

650

1.00

2.13 (1.26-3.59)

3.76 (2.25-6.27)

1.00

2.66 (1.50-4.72)

3.55 (2.00-6.31)

1.00

2.50 (1.44-4.33)

4.50 (2.62-7.72)

1.00

2.47 (1.37-4.45)

3.04 (1.70-5.42)

   ≥65 years

969

1.00

1.21 (0.73-2.03)

1.88 (1.16-3.06)

1.00

1.84 (1.12-3.04)

3.80 (2.31-6.28)

1.00

2.16 (1.12-4.15)

3.87 (2.08-7.19)

1.00

2.16 (1.12-4.15)

3.87 (2.08-7.19)

Alcohol consumption

             

   Absent

829

1.00

1.42 (0.83-2.44)

2.27 (1.34-3.85)

1.00

1.94 (1.16-3.25)

3.04 (1.78-5.10)

1.00

1.11 (0.62-1.98)

2.23 (1.29-3.87)

1.00

4.72 (2.47-9.03)

7.41 (3.81-14.4)

   Present

1090

1.00

1.74 (1.07-2.84)

2.91 (1.82-4.66)

1.00

2.65 (1.54-4.58)

4.89 (2.83-8.44)

1.00

4.50 (2.37-8.54)

7.30 (3.88-13.7)

1.00

1.62 (0.93-2.82)

2.66 (1.55-4.55)

Uric acid

             

   <5.0 (mean) mg/dL

978

1.00

1.51 (0.87-2.60)

3.21 (1.90-5.40)

1.00

2.39 (4.41-4.05)

3.53 (2.07-6.03)

1.00

1.98 (1.11-3.54)

3.57 (2.03-6.29)

1.00

2.79 (1.59-4.89)

3.46 (1.95-6.14)

   ≥5.0 (mean) mg/dL

941

1.00

1.68 (1.03-2.75)

2.14 (1.33-3.44)

1.00

2.24 (1.32-3.79)

4.04 (2.38-6.85)

1.00

1.68 (1.03-2.75)

2.14 (1.33-3.44)

1.00

2.24 (1.32-3.79)

4.04 (2.38-6.85)

HMW adiponectin

             

   <5.03 (median) μg/mL

963

1.00

1.64 (1.02-2.64)

2.74 (1.73-4.32)

1.00

2.63 (1.63-4.23)

3.52 (2.18-5.69)

1.00

2.63 (1.50-4.60)

4.57 (2.66-7.87)

1.00

1.86 (1.11-3.09)

3.23 (1.97-5.30)

   ≥5.03 (median) μg/mL

956

1.00

1.27 (0.71-2.27)

1.53 (0.85-2.75)

1.00

1.79 (0.96-3.34)

3.76 (2.04-6.96)

1.00

1.61 (0.84-3.10)

2.12 (1.11-4.05)

1.00

4.41 (2.07-9.42)

5.09 (2.33-11.1)

Medication‡

             

   Absent

1342

1.00

1.76 (1.09-2.85)

3.11 (1.95-4.93)

1.00

2.02 (1.23-3.31)

3.36 (2.06-5.50)

1.00

3.24 (1.87-5.62)

5.73 (3.34-9.84)

1.00

2.39 (1.43-3.97)

3.05 (1.84-5.07)

   Present

577

1.00

1.18 (0.66-2.09)

1.87 (1.07-3.25)

1.00

2.22 (1.24-3.96)

3.55 (1.95-6.44)

1.00

1.12 (0.57-2.19)

2.07 (1.10-3.88)

1.00

2.94 (1.43-6.06)

6.09 (2.94-12.6)

  1. Metabolic syndrome was defined as having three or more of the following conditions: obesity, raised blood pressure, hypertriglyceridemia, low HDL cholesterolemia, and impaired fasting blood glucose. † Insulin resistance was defined as HOMA-IR ≥2.6. ‡Medication was defined as antihypertensive, antilipidemic, or diabetic medication. Each tertile was calculated within sex and then combined to avoid the gender differences. Values adjusted for sex, age, smoking status, alcohol consumption, uric acid, and estimated glomerular filtration rate.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840